Pioglitazone placebo

DRUG4 trials

Sponsors

Kinarus AG, Takeda, Washington University School of Medicine

Conditions

COVID-19Lung InflammationMild Cognitive Impairment Due to Alzheimer's DiseaseType 2 Diabetes Mellitus

Early Phase 1

Evaluation of Rosiglitazone Anti-inflammatory Effect With FDG-PET Imaging

CompletedNCT01174056

Washington University School of MedicineLung Inflammation

Start: 2011-07-31End: 2014-03-31Updated: 2014-04-23

Phase 2

A 4-week double-blind, randomized, placebo-controlled, phase II study evaluating the effects of oral pamapimod 150 mg with pioglitazone 10 mg daily on COVID-19 evolution and recovery in non-hospitalized patients infected with SARS-CoV-2 (severe acute respiratory syndrome-coronavirus-2)

CompletedCTIS2022-500244-37-00

Kinarus AGCOVID-19

Start: 2022-08-25End: 2025-04-24Target: 150Updated: 2022-09-20

Phase 3

Efficacy and Safety of Alogliptin Combined With Pioglitazone in Treating Subjects With Type 2 Diabetes Mellitus.

CompletedNCT00328627

TakedaType 2 Diabetes Mellitus

Start: 2006-05-31End: 2008-03-31Updated: 2013-04-04

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset

TerminatedNCT01931566

TakedaMild Cognitive Impairment Due to Alzheimer's Disease

Start: 2013-08-01End: 2018-09-06Updated: 2019-09-16

Related Papers

Applying the German Version of the TOMMORROW Neuropsychological Assessment Battery for the diagnosis of Mild Cognitive Impairment in Clinical and Research Settings

Alzheimer s & Dementia2022-12-01

Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial.

2021-07-0186 citations

Classification accuracy goals for diagnostic tests based on risk stratification

Biostatistics & Epidemiology2021-03-171 citations

O4‐11‐02: DEFINING COGNITION IN PRE‐DEMENTIA CLINICAL TRIALS: BASELINE NEUROPSYCHOLOGICAL DATA FROM THE TOMMORROW STUDY

Alzheimer s & Dementia2019-07-01

The peroxisome proliferator-activated receptor agonist pioglitazone and 5-lipoxygenase inhibitor zileuton have no effect on lung inflammation in healthy volunteers by positron emission tomography in a single-blind placebo-controlled cohort study

PLoS ONE2018-02-079 citations

[P1–059]: APPROACHES TO SUBJECT RETENTION IN A PHASE 3 DELAY‐OF‐ONSET OF MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER's DISEASE (MCI‐AD) CLINICAL TRIAL: THE TOMMORROW STUDY EXPERIENCE

Alzheimer s & Dementia2017-07-01

P4‐383: Characterization of the Screened Population for the Tommorrow Study: a Pharmacogenetics‐Supported Clinical Trial to Delay the Onset of Mild Cognitive Impairment Due to Alzheimer’S Disease

Alzheimer s & Dementia2016-07-01

How many unpublished studies? ClinicalTrials.gov (n = 2614 studies): diabetes | Closed Studies | Interventional Studies | Phase 3, 4 | Search Date: Oct 27, 2014

Figshare2014-01-01